Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pliant Therapeutics Inc.

http://pliantrx.com/

Latest From Pliant Therapeutics Inc.

Novartis, Pfizer Advance Their NASH Ambitions Separately, As Partners

Novartis thinks tropifexor may prove to be best-in-class FXR agonist, while Pfizer notes the complementary activity of its ACC and DGAT2 inhibitors. Their NASH trial collaboration is heading toward a Phase II launch in 2020.

Business Strategies Research and Development Strategies

Deal Watch: Gilead Hopes Glympse’s Synthetic Biomarkers Can Optimize NASH Trials

Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.

Deals Business Strategies

Novartis Adds To NASH Pipeline By Licensing Pliant’s Integrin Inhibitor

Deal for preclinical asset adds an anti-fibrotic mechanism to Novartis’ NASH program. Pliant produced preclinical data showing strong anti-fibrotic effect.

Deals Research and Development Strategies

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.

Rare Diseases Pricing Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Gastrointestinal
  • Hepatic (Liver)
  • Inflammation
  • Neurology, Nervous System
  • Renal System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Pliant Therapeutics Inc.
  • Senior Management
  • Bernard Coulie, MD, PhD, Pres. & CEO
    Keith Cummings, MD, CFO
    Hans Hull, CBO
    Eric Lefebvre, MD, CMO
  • Contact Info
  • Pliant Therapeutics Inc.
    Phone: (650) 481-6770
    260 Littlefield Ave
    South San Francisco, CA 94080
    USA
UsernamePublicRestriction

Register